Streetbeat News

Price Targets

GM

Wells Fargo analyst Colin Langan maintains an Underweight rating on General Motors (NYSE:GM) but raises the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 2:09 pm

DAN

Wells Fargo analyst Colin Langan maintains an Equal-Weight rating on Dana (NYSE:DAN) but lowers the price target from $13 to $12.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 2:07 pm

BWA

Wells Fargo analyst Colin Langan maintains an Overweight rating on BorgWarner (NYSE:BWA) but lowers the price target from $45 to $44.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 2:06 pm

ALV

Wells Fargo analyst Colin Langan maintains an Equal-Weight rating on Autoliv (NYSE:ALV) but lowers the price target from $128 to $122.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 2:04 pm

BOWL

B. Riley Securities analyst Eric Wold has reiterated a Buy rating on Bowlero (NYSE:BOWL) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 2:04 pm

ALT

B. Riley Securities has reiterated its Buy rating on Altimmune (NASDAQ:ALT) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 2:03 pm

BLDR

Analysts have provided a range of ratings for Builders FirstSource (NYSE:BLDR) over the past three months, with a mix of bullish, somewhat bullish, and indifferent sentiments. The average 12-month price target has declined by 5.67% to $199.62. Recent analyst actions include both downgrades and upgrades, reflecting varied expectations for the company's future performance.

Portfolio Pulse from Benzinga Insights

June 25, 2024 | 2:01 pm

DKNG

Over the past three months, 23 analysts have evaluated DraftKings (NASDAQ:DKNG), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $54.04. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a generally positive outlook.

Portfolio Pulse from Benzinga Insights

June 25, 2024 | 2:01 pm

TXG

In the past three months, 9 analysts have provided ratings for 10x Genomics (NASDAQ:TXG), showing a range of sentiments from bullish to bearish. The average 12-month price target has decreased by 26.94% to $39.0. Analysts have recently lowered their price targets, reflecting a negative shift in sentiment.

Portfolio Pulse from Benzinga Insights

June 25, 2024 | 2:00 pm